These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 21677109

  • 1. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.
    Aase A, Herstad TK, Merino S, Bolstad M, Sandbu S, Bakke H, Aaberge IS.
    Clin Vaccine Immunol; 2011 Aug; 18(8):1269-74. PubMed ID: 21677109
    [Abstract] [Full Text] [Related]

  • 2. Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age.
    Aase A, Herstad TK, Jørgensen SB, Leegaard TM, Berbers G, Steinbakk M, Aaberge I.
    Vaccine; 2014 Oct 14; 32(45):5931-6. PubMed ID: 25218299
    [Abstract] [Full Text] [Related]

  • 3. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ, Han SB, Kim BR, Kang KR, Huh DH, Choi GS, Ahn DH, Kang JH.
    BMC Infect Dis; 2017 Apr 04; 17(1):247. PubMed ID: 28376777
    [Abstract] [Full Text] [Related]

  • 4. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A, Stage III Working Group.
    Pediatrics; 2001 Nov 04; 108(5):E81. PubMed ID: 11694665
    [Abstract] [Full Text] [Related]

  • 5. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
    Stenger RM, Smits M, Kuipers B, van Gaans-van den Brink J, Poelen M, Boog CJ, van Els CA.
    Vaccine; 2010 Sep 14; 28(40):6637-46. PubMed ID: 20637762
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M, Rathi N, Kuriyakose S, Hardt K, Schwarz TF.
    Vaccine; 2015 May 21; 33(22):2594-601. PubMed ID: 25882172
    [Abstract] [Full Text] [Related]

  • 7. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
    Ladhani SN, Andrews NJ, Southern J, Jones CE, Amirthalingam G, Waight PA, England A, Matheson M, Bai X, Findlow H, Burbidge P, Thalasselis V, Hallis B, Goldblatt D, Borrow R, Heath PT, Miller E.
    Clin Infect Dis; 2015 Dec 01; 61(11):1637-44. PubMed ID: 26374816
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
    Hendrikx LH, Berbers GA, Veenhoven RH, Sanders EA, Buisman AM.
    Vaccine; 2009 Nov 05; 27(47):6530-6. PubMed ID: 19729085
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C, Chanthavanich P, Limkittikul K, Siegrist CA, Wijagkanalan W, Chinwangso P, Petre J, Hong Thai P, Chauhan M, Viviani S.
    Hum Vaccin Immunother; 2017 Jan 02; 13(1):136-143. PubMed ID: 27686283
    [Abstract] [Full Text] [Related]

  • 15. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A, Bona G, Canciani G, Pistilli AM, Contu B, Furlan R, Meloni T, Stramare D, Titone L, Rappuoli R.
    J Pediatr; 1995 Aug 02; 127(2):238-43. PubMed ID: 7636648
    [Abstract] [Full Text] [Related]

  • 16. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
    Blanchard Rohner G, Chatzis O, Chinwangso P, Rohr M, Grillet S, Salomon C, Lemaître B, Boonrak P, Lawpoolsri S, Clutterbuck E, Poredi IK, Wijagkanalan W, Spiegel J, Pham HT, Viviani S, Siegrist CA.
    Clin Infect Dis; 2019 Mar 19; 68(7):1213-1222. PubMed ID: 30759183
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
    Wood N, Nolan T, Marshall H, Richmond P, Gibbs E, Perrett K, McIntyre P.
    JAMA Pediatr; 2018 Nov 01; 172(11):1045-1052. PubMed ID: 30208475
    [Abstract] [Full Text] [Related]

  • 18. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
    Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME.
    Arch Pediatr Adolesc Med; 1994 May 01; 148(5):503-7. PubMed ID: 8180641
    [Abstract] [Full Text] [Related]

  • 19. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
    Knuf M, Vetter V, Celzo F, Ramakrishnan G, Van Der Meeren O, Jacquet JM.
    Hum Vaccin; 2010 Jul 01; 6(7):554-61. PubMed ID: 20448468
    [Abstract] [Full Text] [Related]

  • 20. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP.
    Pediatr Infect Dis J; 2008 Apr 01; 27(4):341-6. PubMed ID: 18316985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.